Estrogens, Conjugated Tablet, Film Coated
Product Images NDC 50742-388

This is a description of Conjugated Estrogens Tablets, USP, containing 0.3 mg of estrogens per tablet. The prescription information advises storing the tablets in tight, light-resistant containers at temperatures between 20-25°C (68-77°F) with excursions permitted between 15-30°C (50-86°F). It also includes a warning to keep the medication out of the reach of children. The usual dosage and additional information are meant to be provided along with dispensing the prescription. The provided expiration date is not available.*

This is a description for Conjugated Estrogens Tablets, USP. Each tablet contains 0.45 mg of conjugated estrogens. It is advised to store the tablets in a dry place at a temperature range of 20-25°C (68.77°F). The usual dosage should be followed as per the accompanying descriptive information. Remember to keep all medications out of the reach of children. The GTIN for this product is 00350742388011.*

This text provides information about Conjugated Estrogens Tablets, USP. Each tablet contains 0.625 mg of conjugated estrogens in their naturally occurring form. The prescription should be dispensed with caution using automated systems. The medication should be stored in a tight, light-resistant container at temperatures between 20-25°C (68-77°F), with excursions allowed between 15-30°C (59-86°F). A warning is given to keep all medications out of the reach of children. The usual dosage information is mentioned, and the prescription is for 100 tablets. The text also includes a GTIN and an expiration date but lacks specific dosage instructions.*

This is a table presenting data from the Estrogen Alone Substudy of WHI, showing the relative and absolute risk comparisons for various health events between women taking estrogen and a placebo. The events include CHD, non-fatal heart attack, stroke, fractures, cancer, and mortality. The data is based on an average follow-up of 7.1 years, and it provides valuable insights into the impact of estrogen-alone therapy on women's health. For more information, the WHI publications can be accessed online.*

The text provides a detailed table presenting the Relative and Absolute Risk observed in the Estrogen Plus Progestin Substudy of the Women's Health Initiative (WHI) over an average of 5.6 years. The table includes information on different health events such as coronary heart disease, strokes, cancer types, fractures, and mortality rates. Each risk is quantified by the Relative Risk of CE/MPA compared to Placebo, the number of cases, and the associated Absolute Risk per 10,000 Women-Years. The data is based on centrally adjudicated information and presents results from various WHI publications. The document mentions that the results are not adjusted for multiple looks and multiple comparisons, and it includes details about the Global Index, which accounts for specific events in the study. The table also clarifies some exceptions and inclusions in the reported events. For more information, individuals are directed to visit the specified website for WHI publications.*

This text provides information about the cumulative percentage change from baseline in spine bone mineral density (% change from baseline in spine BMD) for different subjects. The data seems to be presented in a table format with different percentages and placeholder values.*